JP2012532134A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532134A5
JP2012532134A5 JP2012518575A JP2012518575A JP2012532134A5 JP 2012532134 A5 JP2012532134 A5 JP 2012532134A5 JP 2012518575 A JP2012518575 A JP 2012518575A JP 2012518575 A JP2012518575 A JP 2012518575A JP 2012532134 A5 JP2012532134 A5 JP 2012532134A5
Authority
JP
Japan
Prior art keywords
seq
nos
amino acid
polypeptide
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012518575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532134A (ja
JP5931724B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/040406 external-priority patent/WO2011008548A1/en
Publication of JP2012532134A publication Critical patent/JP2012532134A/ja
Publication of JP2012532134A5 publication Critical patent/JP2012532134A5/ja
Application granted granted Critical
Publication of JP5931724B2 publication Critical patent/JP5931724B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012518575A 2009-06-29 2010-06-29 StreptococcusPneumoniaeに対するワクチンおよび組成物 Expired - Fee Related JP5931724B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US22154109P 2009-06-29 2009-06-29
US61/221,541 2009-06-29
US24059809P 2009-09-08 2009-09-08
US24061609P 2009-09-08 2009-09-08
US61/240,598 2009-09-08
US61/240,616 2009-09-08
US31626710P 2010-03-22 2010-03-22
US61/316,267 2010-03-22
PCT/US2010/040406 WO2011008548A1 (en) 2009-06-29 2010-06-29 Vaccines and compositions against streptococcus pneumoniae

Publications (3)

Publication Number Publication Date
JP2012532134A JP2012532134A (ja) 2012-12-13
JP2012532134A5 true JP2012532134A5 (enExample) 2014-04-03
JP5931724B2 JP5931724B2 (ja) 2016-06-08

Family

ID=43449681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012518575A Expired - Fee Related JP5931724B2 (ja) 2009-06-29 2010-06-29 StreptococcusPneumoniaeに対するワクチンおよび組成物

Country Status (15)

Country Link
US (2) US10105412B2 (enExample)
EP (1) EP2448592B1 (enExample)
JP (1) JP5931724B2 (enExample)
KR (1) KR101748453B1 (enExample)
CN (2) CN107126557A (enExample)
AU (1) AU2010273708B2 (enExample)
BR (1) BRPI1011919A2 (enExample)
CA (1) CA2803061A1 (enExample)
IL (1) IL217166A0 (enExample)
IN (1) IN2012DN00791A (enExample)
MX (1) MX2012000158A (enExample)
NZ (1) NZ597858A (enExample)
RU (1) RU2580299C2 (enExample)
SG (2) SG10201403702SA (enExample)
WO (1) WO2011008548A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107126557A (zh) 2009-06-29 2017-09-05 健诺西生物科学公司 抗肺炎链球菌的疫苗和组合物
EP3165531B1 (en) 2010-03-12 2020-11-25 Children's Medical Center Corporation Immunogenic composition, vaccine, and uses thereof
PL2656070T3 (pl) * 2010-12-21 2017-01-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Oznaczanie skuteczności żywej rekombinowanej szczepionki anty-mykobakteryjnej
WO2012100234A1 (en) * 2011-01-20 2012-07-26 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae
AR085698A1 (es) * 2011-03-09 2013-10-23 Glaxosmithkline Llc Inhibidores de la peptido desformilasa
CN108840912B (zh) 2011-05-11 2023-07-04 儿童医疗中心有限公司 修饰的生物素结合蛋白及其融合蛋白和应用
AU2013209513B2 (en) * 2012-01-20 2017-10-05 Children's Medical Center Corporation Fused antigen vaccines and compositions against Streptococcus pneumoniae
WO2014018904A1 (en) * 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
CA2900008C (en) 2013-02-07 2025-10-07 Children's Medical Center Corporation PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
US20150079132A1 (en) * 2013-09-17 2015-03-19 Path Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly
WO2015161218A1 (en) * 2014-04-18 2015-10-22 Children's Medical Center Corporation Vaccine adjuvant compositions
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018183475A1 (en) 2017-03-28 2018-10-04 Children's Medical Center Corporation A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
MX2019015524A (es) 2017-06-23 2020-09-10 Univ Maryland Composiciones inmunogenicas.
MX2020005584A (es) 2017-12-04 2020-09-14 Intervet Int Bv Vacunacion con particulas de replicon y adyuvante oleoso.
TWI852943B (zh) 2018-09-12 2024-08-21 美商兒童醫療中心公司 肺炎鏈球菌融合蛋白疫苗
IL281204B2 (en) 2018-09-12 2025-07-01 Affinivax Inc Multivalent pneumococcal vaccines
RU2728938C1 (ru) * 2020-05-06 2020-08-03 Федеральное государственное бюджетное учреждение науки "Научный центр биомедицинских технологий Федерального медико-биологического агентства" (ФГБУН НЦБМТ ФМБА России) Применение даларгина для производства лекарственных средств профилактики пневмонии
US12350324B2 (en) 2020-07-16 2025-07-08 Zalvac Ab Streptococcal vaccines
AU2022342080A1 (en) 2021-09-09 2024-03-28 Affinivax, Inc. Multivalent pneumococcal vaccines

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5371197A (en) 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
WO1997037026A1 (en) 1996-04-02 1997-10-09 Smithkline Beecham Corporation Novel compounds
CA2271720A1 (en) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
EP0981625A2 (en) 1997-05-06 2000-03-01 Human Genome Sciences, Inc. $i(ENTEROCOCCUS FAECALIS) POLYNUCLEOTIDES AND POLYPEPTIDES
AU8151898A (en) 1997-06-20 1999-01-04 Human Genome Sciences, Inc. Lyme disease vaccines
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US5882885A (en) 1997-07-17 1999-03-16 Smithkline Beecham Corporation Glycogen phosphorylase
US5994101A (en) 1997-07-18 1999-11-30 Smithkline Beecham Corporation DNA encoding gidA1 polypeptides
US6617156B1 (en) 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
WO2000006738A2 (en) 1998-07-27 2000-02-10 Microbial Technics Limited NUCLEIC ACIDS AND PROTEINS FROM $i(STREPTOCOCCUS PNEUMONIAE)
US6887480B1 (en) 1999-06-10 2005-05-03 Medimmune, Inc. Streptococcus pneumoniae proteins and vaccines
WO2000076540A2 (en) 1999-06-10 2000-12-21 Med Immune, Inc. Streptococcus pneumoniae proteins and vaccines
EP1905834A3 (en) 1999-12-23 2008-07-23 Vmax Limited Virulence Genes, Proteins, and their Use
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
ATE439372T1 (de) * 2000-10-27 2009-08-15 Novartis Vaccines & Diagnostic Nukleinsäuren und proteine von gruppen a und b- streptokokken
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
CN1636062A (zh) 2001-04-16 2005-07-06 惠氏控股公司 编码多肽抗原的新肺炎链球菌可读框及其应用
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US20090252756A1 (en) 2002-04-02 2009-10-08 Yaffa Mizrachi-Nebenzahl Protein-based streptococcus pneumoniae vaccines
EP2275120A3 (en) 2002-04-02 2011-06-08 Ben-Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
WO2004018646A2 (en) 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
WO2004020609A2 (en) 2002-08-30 2004-03-11 Tufts University Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
EP2333114A1 (en) 2003-04-15 2011-06-15 Intercell AG S. pneumoniae antigens
GB0318688D0 (en) 2003-08-08 2003-09-10 Chiron Srl Streptococcus pneumoniae knockout mutants
WO2006069200A2 (en) 2004-12-22 2006-06-29 Novartis Vaccines And Diagnostics Inc. Group b streptococcus
KR20070122458A (ko) 2005-02-11 2007-12-31 에이스 바이오사이언시즈 에이/에스 표재성 스트렙토코커스 뉴모니아 폴리펩티드
AU2007225238A1 (en) 2006-03-10 2007-09-20 Wyeth Microarray for monitoring gene expression in multiple strains of Streptococcus pneumoniae
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
WO2008119358A2 (en) 2007-03-30 2008-10-09 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides for use in vaccine compositions
EP2155912B1 (en) 2007-05-18 2013-06-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Primers and probes for the detection of streptococcus pneumoniae
ES2381613T3 (es) 2007-05-25 2012-05-29 Novartis Ag Antígenos de pilus de streptococcus pneumoniae
US20100247547A1 (en) 2007-05-29 2010-09-30 Chen Dong Modulation of the th-17 cell mediated immune responses
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009033742A2 (en) * 2007-09-14 2009-03-19 Katholieke Universiteit Leuven Streptococcus pneumoniae vaccines
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US7833776B2 (en) 2007-12-12 2010-11-16 National Health Research Institutes Lipidating sequences and use thereof for producing lipidated proteins in E. coli
JP5779352B2 (ja) * 2008-03-14 2015-09-16 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 複製欠損フラビウイルスワクチンおよびワクチンベクター
AU2009266924B2 (en) 2008-07-01 2015-12-10 Genocea Biosciences, Inc. Antigen screening system
BRPI0922132A2 (pt) 2008-12-03 2018-10-23 Protea Vaccine Tech Ltd fragmentos glutamil trna sintetase (gts).
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
WO2010148496A1 (en) 2009-06-22 2010-12-29 National Health Research Institutes Lipidated tumor- associated antigens and immunotherapeutic compositions
US20120100172A1 (en) 2009-06-25 2012-04-26 Michael Tal Immunogenic streptococcus pneumoniae peptides and peptide-multimers
CN107126557A (zh) 2009-06-29 2017-09-05 健诺西生物科学公司 抗肺炎链球菌的疫苗和组合物
WO2011064781A1 (en) 2009-11-30 2011-06-03 Ben-Gurion University Of The Negev Research And Development Authority S. pneumoniae adhesins
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
JP5065434B2 (ja) 2010-04-06 2012-10-31 株式会社日立製作所 管理方法及び管理装置
WO2011128892A2 (en) 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
US20110283062A1 (en) 2010-05-14 2011-11-17 Hitachi, Ltd. Storage apparatus and data retaining method for storage apparatus
WO2012100234A1 (en) 2011-01-20 2012-07-26 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae

Similar Documents

Publication Publication Date Title
RU2011153032A (ru) Вакцины и композиции, направленные против streptococcus pneumoniae
ES2741729T3 (es) Vectores y construcciones de liberación de antígenos de virus de la gripe
RU2013138563A (ru) Вакцины и композиции против streptococcus pneumoniae
AU2006322907B2 (en) Improved influenza vaccine
JP2008530245A5 (enExample)
JP2012500001A5 (enExample)
JP2012136541A5 (enExample)
JP2020023567A5 (enExample)
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
JP2010508030A5 (enExample)
JP2011524737A5 (enExample)
JP2014521605A5 (enExample)
JP2010532656A5 (enExample)
CN1578672A (zh) Rsv基因表达疫苗
JP2014502961A5 (enExample)
JP2013505017A5 (enExample)
RU2013126888A (ru) ИММУНОМОДУЛИРУЮЩИЕ КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ, СОДЕРЖАЩИЕ ИММУНОГЕННЫЕ ФРАГМЕНТЫ АроВ100
JP2013523084A5 (enExample)
JP2015513314A5 (enExample)
Zhao et al. Cross-protection against homo and heterologous influenza viruses via intranasal administration of an HA chimeric multiepitope nanoparticle vaccine
WO2012162637A3 (en) Vaccine adjuvants from self-assembling peptides
JP2018135388A (ja) シュードモナス抗原および抗原の組み合わせ
JP2019534242A5 (enExample)
CN102816221A (zh) 鸡柔嫩艾美耳球虫ma1基因、载体、重组菌株和蛋白及其应用
Schulze et al. A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus